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Available online 17 May 2016Expanded human T cells from a Japanese female with recessive dystrophic epidermolysis bullosa (RDBE) were
used to generate integration-free induced pluripotent stem cells (iPSCs) by exogenous expression of four
reprogramming factors, OCT3/4, SOX2, cMYC, KLF4, using Sendai virus vector (SeVdp). The authenticity of
established iPSC line, RDEB-iPSC26, was conﬁrmed by the expressions of stem cell markers and the differentia-
tion capability into three germ layer. RDEB-iPSC26 may be a useful cell resource for the establishment of in
vitro RDEB modeling and the study for developing gene and cell therapy.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Recessive dystrophic epidermolysis bullosa (RDEB) is an
inherited skin blistering disorder caused by mutations in the
COL7A1 gene encoding type VII collagen, the major component
of anchoring ﬁbrils at the basement membrane zone. RDEB is
characterized by skin fragility, resulting in recurrent and incur-
able blisters. Since skin biopsy is borne by RDEB patients, we uti-
lized peripheral blood cells for generating iPSCs. Expanded T cells
isolated from a patient with RDEB were reprogrammed
employing Sendai virus vectors (SeVdp) expressing four
reprogramming factors, OCT3/4, SOX2, cMYC, KLF4. SeVdp is inte-
gration-free vector, and the absence of reprogramming genes in
established iPSC line, RDEB-iPSC26, was conﬁrmed by PCR analy-
sis (Fig. 1A). The same pathogenic mutation in the COL7A1 gene
was also detected in genomic DNA isolated from RDEB-iPSC26
(Fig. 1B), proving the origin of cell source. The authenticity of
RDEB-iPSC26 was conﬁrmed by the followings; (1) the expres-
sion of stem cell markers by immunostaining (Fig. 1C) and RT-
PCR (Fig. 1D), (2) the differentiation capability into three germ
layers using in vitro differentiation through embryoid bodies
(EBs) and teratoma formation (Fig. 1E). In addition, RDEB-
iPSC26 maintains normal karyotype (46, XX) (Fig. 1F), and bisul-
ﬁte sequencing revealed that the NANOG promoter region in
RDEB-iPSC26 was unmethylated (Fig. 1G).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Characterization of RDEB-iPSC26. (A) Conﬁrmation of the absent of SeVdp-related
reprogramming gene by RT-PCR (M: marker, #26: RDEB-iPSC26, C: control transfected
cell sample). (B) The same pathogenic mutation in the COL7A1 gene was detected from
genomic DNA isolated from RDEB-iPSC26. The expression of stem cell markers in RDEB-
iPSC26 was detected by immunostaining (C) and RT-PCR (D, red square) (E: embryonic
stem cell cDNA, M: monocyte cDNA). (E) Embryoid body and teratoma formation
indicated the differentiation capability into three germ layer, ectoderm (βIII-tubulin and
neural epithelium), mesoderm (vimentin and cartilage) and endoderm (α-fetoprotein
and gut epithelium). (F) Karyotype was normal (46, XX). (G) The NANOG promoter
region in RDEB-iPSC26 was almost completely unmethylated (White circle:
unmethylated CpGs, black circle: methylated CpGs). All the data suggested the
authenticity of RDEB-iPSC26.
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2.1. Patient information
A 38-year-old Japanese female suffered frommany cutaneous blisters,
erosions, ulcers and scars as a result of gentle mechanical trauma since
birth. Her ﬁngers had adhered to each other, resulting in
pseudosyndactyly. Their nails were deformed and some nail plates were
lost. Sequencing analysis in theCOL7A1 gene identiﬁed that the pathogen-
ic mutations were two compound heterozygous mutations, c.2005C N T
(p.R669*) at exon 15 and c.8569G N T (p.E2857*) at exon 116, resulting
in abnormal type VII collagen production.2.2. Cell culture
Monocytes was isolated from the patient's peripheral blood sample
using SepMate™-50 (STEMCELL technologies, Inc., Canada) and Ficoll-
Paque Plus (GE Healthcare). Consequently, T cell was expanded in TLY
culture® kit (LYMPHOTEC, Inc., Japan) for 5–10 days at 37 °C at 5% CO2.
2.3. iPSC generation
Expanded T cells were reprogrammed by SeVdp as previously de-
scribed (Nishimura et al., 2011) and (Itoh et al., 2016). Brieﬂy, the
transfected cells were seeded on feeder cell layer in RPMI1640 with 10%
fetal bovine serum and interleukin-2 (PeproTech). After 2 days, themedi-
um was changed to Primate ES cell culture medium (ReproCELL Inc.,
Japan) supplemented with basic ﬁbroblast growth factor (bFGF) (5 ng/
mL, R&D Systems), and cultured until colonies appeared. Established
iPSCs were maintained in human iPS cell medium (Itoh et al., 2016). To
completely remove SeVdp, siRNA mixture (Itoh et al., 2016) was added
several times into the medium.
2.4. Sequencing
Sanger sequencing analysis of the mutation site in the COL7A1 gene
was performed in Applied Biosystems 3730xI DNA analyzer, using the
ABI Prism Big Dye Terminator Cycle Sequencing Ready Reaction Kit ver.
3.1. (Applied Biosystems). Primers for sequence are the follows; exon
15 forward: 5′-ATCACTGCCATCGTCCCACATC-3′, exon 15 reverse: 5′-
GGTCTGAAAGAGCAATGGAG-3′, exon 116 forward: 5′-
ACAGTGGAAATCAGTGCTGC-3′, and exon 116 reverse: 5′-
AGGGTTTGTGGGAATCAGAG-3′.
2.5. RT-PCR
RNAwas extracted using an RNeasy Mini Kit (Qiagen), and comple-
mentary DNAwas synthesized using 2 μg RNA by SuperScript III reverse
transcriptase and Oligo-dT primer (Invitrogen) according to the
manufacturer's instructions. PCR reactions were performed with Plati-
num PCR SuperMix (Invitrogen). All primer sequences are supplied in
(Itoh et al., 2011, 2016).
2.6. Immunostaining
iPSCs and EBs were ﬁxed with 4% paraformaldehyde(PFA)/PBS and
permeabilized with 0.1% Triton-×100/PBS. After blocking using 10%
goat sera/PBS, samples were incubated for 1 h at room temperature
(RT) or overnight at 4 °C with primary antibodies. After three rinses
with PBS, incubation with appropriate secondary antibodies was per-
formed for 1 h at RT. Nuclei staining was performed with Hoechst
(1:1000)/PBS. Conforcalmicroscopy (OLYMPUS FV-300)was used to vi-
sualize and capture the immunostained cells with good resolution. All
antibodies are supplied in (Itoh et al., 2016).
2.7. Karyotyping analysis
Karyotyping analysis was offered to Nihon Gene Research Laborato-
ries, Inc., Japan.
2.8. Methylation assay
A total of 1 μg genomic DNA extracted from RDEB-iPSC26was treated
with EZ DNA Methylation-Gold Kit (ZYMO Research, Corp.) for bisulﬁte
reaction. The promoter region of the NANOG gene was ampliﬁed by PCR
using gene-speciﬁc primers (Itoh et al., 2011). PCRproductwas subcloned
into pCR2.1 vector (Invitrogen), and 10 clones were sequenced for deﬁn-
ing methylation status of the NANOG promoter region.
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EBs were made in hiPSCM without bFGF as previously described in
(Itoh et al., 2011) For enhancing spontaneous differentiation, EBs were
attached on gelatin-coated chamber slides and incubated in DMEM
with 10% FBS for 14 days before immunostaining.
2.10. Teratoma formation
Colonies of RDEB-iPSC26 were collected by 1 mg/mL collagenase IV
(Invitrogen) treatment and subcutaneously injected into nude mice
(CLEA Japan, Inc.) withMatrigel (Corning, Inc.). Palpable tumors typically
appeared 1–2 months after injection. Tumors were collected and proc-
essed for H&E staining according to standard procedures to check their
differentiation capacity into all three germ layers in vivo.
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